JP6324725B2 - 発現系 - Google Patents

発現系 Download PDF

Info

Publication number
JP6324725B2
JP6324725B2 JP2013546722A JP2013546722A JP6324725B2 JP 6324725 B2 JP6324725 B2 JP 6324725B2 JP 2013546722 A JP2013546722 A JP 2013546722A JP 2013546722 A JP2013546722 A JP 2013546722A JP 6324725 B2 JP6324725 B2 JP 6324725B2
Authority
JP
Japan
Prior art keywords
nep
pb1f2
protein
virus
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013546722A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014504500A5 (enExample
JP2014504500A (ja
Inventor
アレッサンドラ・ヴィテッリ
アルフレド・ニコシア
リカルド・コルテーゼ
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2014504500A publication Critical patent/JP2014504500A/ja
Publication of JP2014504500A5 publication Critical patent/JP2014504500A5/ja
Application granted granted Critical
Publication of JP6324725B2 publication Critical patent/JP6324725B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2013546722A 2010-12-30 2011-12-30 発現系 Expired - Fee Related JP6324725B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2010/007995 WO2012089231A1 (en) 2010-12-30 2010-12-30 Paramyxovirus vaccines
EPPCT/EP2010/007995 2010-12-30
PCT/EP2011/074307 WO2012089833A2 (en) 2010-12-30 2011-12-30 Expression Systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017004556A Division JP2017079787A (ja) 2010-12-30 2017-01-13 発現系

Publications (3)

Publication Number Publication Date
JP2014504500A JP2014504500A (ja) 2014-02-24
JP2014504500A5 JP2014504500A5 (enExample) 2015-02-19
JP6324725B2 true JP6324725B2 (ja) 2018-05-16

Family

ID=45464575

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013546722A Expired - Fee Related JP6324725B2 (ja) 2010-12-30 2011-12-30 発現系
JP2017004556A Pending JP2017079787A (ja) 2010-12-30 2017-01-13 発現系

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017004556A Pending JP2017079787A (ja) 2010-12-30 2017-01-13 発現系

Country Status (23)

Country Link
US (4) US20140141042A1 (enExample)
EP (2) EP2658573B1 (enExample)
JP (2) JP6324725B2 (enExample)
KR (1) KR102070463B1 (enExample)
CN (1) CN103442731B (enExample)
AU (2) AU2011351380A1 (enExample)
BR (1) BR112013016823A2 (enExample)
CA (1) CA2821111A1 (enExample)
CY (1) CY1124146T1 (enExample)
DK (1) DK2658573T3 (enExample)
ES (1) ES2869199T3 (enExample)
HR (1) HRP20210750T1 (enExample)
HU (1) HUE053986T2 (enExample)
IL (1) IL226551B (enExample)
LT (1) LT2658573T (enExample)
MX (1) MX352205B (enExample)
NZ (1) NZ610743A (enExample)
PL (1) PL2658573T3 (enExample)
PT (1) PT2658573T (enExample)
RU (1) RU2609645C2 (enExample)
SG (2) SG190919A1 (enExample)
SI (1) SI2658573T1 (enExample)
WO (2) WO2012089231A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2869841B1 (en) 2012-07-05 2021-08-25 GlaxoSmithKline Biologicals SA Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
SI2879702T1 (sl) * 2012-08-01 2020-02-28 Bavarian Nordic A/S Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV)
ES2767324T3 (es) * 2012-08-01 2020-06-17 Bavarian Nordic As Vacuna de virus vaccinia modificado de Ankara (MVA) recombinante para el virus sincicial respiratorio (VRS)
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
RS60056B1 (sr) * 2013-02-01 2020-04-30 Medimmune Llc Epitopi f proteina respiratornog sincicijalnog virusa
US20140286981A1 (en) * 2013-03-14 2014-09-25 Wisconsin Alumni Research Foundation Broadly reactive mosaic peptide for influenza vaccine
HRP20200012T1 (hr) 2013-03-15 2020-03-20 The Research Foundation Of The State University Of New York Atenuirani virusi i cjepiva gripe
SG11201600709TA (en) 2013-08-05 2016-02-26 Glaxosmithkline Biolog Sa Combination immunogenic compositions
EP3154576A1 (en) 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
WO2016198621A1 (en) 2015-06-12 2016-12-15 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
DE20164728T1 (de) * 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
GB201614485D0 (en) 2016-08-25 2016-10-12 Univ Oxford Innovation Ltd Immunogenic composition
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
JP7118062B2 (ja) 2016-12-09 2022-08-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム リサウイルス抗原を有するチンパンジーアデノウイルス構築物
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
GB201701239D0 (en) 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
CN107119064A (zh) * 2017-02-21 2017-09-01 南京农业大学 重组枯草芽孢杆菌串联表达禽流感病毒ha抗原片段和pb1－f2蛋白
US20200299651A1 (en) 2017-10-16 2020-09-24 Glaxosmithkline Biologicals Sa Simian adenoviral vectors with two expression cassettes
US11859199B2 (en) 2017-10-16 2024-01-02 Glaxosmithkline Biologicals Sa Adenoviral vectors with two expression cassettes encoding RSV antigenic proteins or fragments thereof
MX394509B (es) 2017-10-16 2025-03-12 Glaxosmithkline Biologicals Sa Promotor mejorado
CN111386126B (zh) * 2017-10-25 2024-01-30 Nouscom股份公司 真核细胞系
KR20200101394A (ko) 2017-12-20 2020-08-27 글락소스미스클라인 바이오로지칼즈 에스.에이. 엡스타인-바 바이러스 항원 구축물
MX2020013553A (es) 2018-06-12 2021-02-26 Glaxosmithkline Biologicals Sa Polinucleotidos y polipeptidos de adenovirus.
WO2020014656A1 (en) * 2018-07-13 2020-01-16 University Of Georgia Research Foundation Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof
CN109180820B (zh) * 2018-09-19 2021-06-25 天康生物制药有限公司 马流感病毒h3n8亚型的融合蛋白及其制备方法、应用和疫苗
US12064478B2 (en) 2018-09-21 2024-08-20 Nutech Ventures Methods of making and using universal centralized influenza vaccine genes
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
CN112220921B (zh) * 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135312B2 (en) * 1993-04-15 2006-11-14 University Of Rochester Circular DNA vectors for synthesis of RNA and DNA
DE19651443A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
US7655774B2 (en) 2000-02-18 2010-02-02 University Of Washington Ancestral and COT viral sequences, proteins and immunogenic compositions
US20040096451A1 (en) * 2002-07-25 2004-05-20 Young James F. Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
WO2003028759A1 (en) 2001-09-28 2003-04-10 University Of South Florida Rsv gene expression vaccine
MXPA04004876A (es) * 2001-11-21 2004-07-30 Univ Pennsylvania Secuencias de acido nucleico y de aminoacido de adenovirus de simio, vectores que contienen los mismos y metodos de uso.
TWI344991B (en) * 2002-02-21 2011-07-11 Medimmune Vaccines Inc Metapneumovirus strains as vaccine formulations and as vectors for expression of heterologous antigenic sequences
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
EP1633312A4 (en) * 2003-06-16 2012-09-26 Medimmune Llc INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS
JP4814800B2 (ja) 2004-01-23 2011-11-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー チンパンジーアデノウイルスワクチン担体
WO2007126887A2 (en) * 2006-03-27 2007-11-08 The Government Of The United States Of America Immunogenic compositions comprising polynucleotides encoding matrix protein 2 and methods of use
EP2023952B1 (en) * 2006-05-18 2015-07-15 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
US9422342B2 (en) * 2006-07-13 2016-08-23 Institute Of Advanced Study Recoding method that removes inhibitory sequences and improves HIV gene expression
DE202007018643U1 (de) 2006-09-05 2009-01-02 BSH Bosch und Siemens Hausgeräte GmbH Bodendüse für Hartböden
WO2008133663A2 (en) * 2006-11-30 2008-11-06 Government Of The United States Of America, As Represented By The Secretary, Codon modified immunogenic compositions and methods of use
WO2009092113A2 (en) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
US20100040650A1 (en) * 2008-05-30 2010-02-18 Crowe Jr James E Virus-Like paramyxovirus particles and vaccines
CA2726914A1 (en) * 2008-06-03 2009-12-10 Okairos Ag A vaccine for the prevention and therapy of hcv infections
JP5781929B2 (ja) * 2008-07-15 2015-09-24 ノバルティス アーゲー 免疫原性の両親媒性ペプチド組成物
WO2010077712A1 (en) * 2008-12-09 2010-07-08 Novavax, Inc. Bovine respiratory syncytial virus virus-like particle (vlps)
ES2987238T3 (es) * 2008-12-09 2024-11-14 Novavax Inc Proteínas F del RSV modificadas y métodos de su uso
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
HUE039908T2 (hu) 2009-02-02 2019-02-28 Glaxosmithkline Biologicals Sa Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk

Also Published As

Publication number Publication date
RU2013135498A (ru) 2015-02-10
SI2658573T1 (sl) 2021-06-30
AU2017203189A1 (en) 2017-07-20
KR20130132894A (ko) 2013-12-05
CN103442731B (zh) 2018-02-27
DK2658573T3 (da) 2021-05-10
US20200360509A1 (en) 2020-11-19
NZ610743A (en) 2015-07-31
HRP20210750T1 (hr) 2021-11-12
IL226551B (en) 2018-04-30
PL2658573T3 (pl) 2021-08-16
CN103442731A (zh) 2013-12-11
EP3868397A1 (en) 2021-08-25
AU2011351380A1 (en) 2013-06-06
EP2658573A2 (en) 2013-11-06
CA2821111A1 (en) 2012-07-05
WO2012089833A3 (en) 2012-09-13
MX2013007716A (es) 2013-08-09
EP2658573B1 (en) 2021-02-24
JP2017079787A (ja) 2017-05-18
AU2017203189B2 (en) 2019-06-27
US11701422B2 (en) 2023-07-18
HUE053986T2 (hu) 2021-08-30
WO2012089231A1 (en) 2012-07-05
MX352205B (es) 2017-11-13
BR112013016823A2 (pt) 2017-06-13
PT2658573T (pt) 2021-05-21
ES2869199T3 (es) 2021-10-25
SG10201510760WA (en) 2016-01-28
US20240075125A1 (en) 2024-03-07
US20140141042A1 (en) 2014-05-22
RU2609645C2 (ru) 2017-02-02
SG190919A1 (en) 2013-07-31
US20170049879A1 (en) 2017-02-23
WO2012089833A2 (en) 2012-07-05
CY1124146T1 (el) 2022-05-27
LT2658573T (lt) 2021-05-25
JP2014504500A (ja) 2014-02-24
KR102070463B1 (ko) 2020-01-29

Similar Documents

Publication Publication Date Title
US20240075125A1 (en) Expression systems
US9849172B2 (en) Influenza virus vaccines and uses thereof
AU2013362935B2 (en) Influenza virus vaccines and uses thereof
JP6244358B2 (ja) ポリヌクレオチドによりコードされた免疫原性ポリペプチドに関わる新規プライムブースト投与法
US9474798B2 (en) Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EP2670430B1 (en) Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses
EP1631673A2 (en) Recombinant influenza vectors with a polii promoter and ribozymes
JP2023524990A (ja) ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質を発現する組換えニューカッスル病ウイルス及びその使用
US11160858B2 (en) Live recombinant measles-M2 virus—its use in eliciting immunity against influenza viruses
CA3158412A1 (en) Recombinant neuraminidase and uses thereof
JP7858592B2 (ja) インフルエンザｂウイルス変異体およびその使用
CN117098551A (zh) 编码截短的ns1蛋白和sars-cov受体结合域的流感病毒
CN116888139A (zh) 诱导高水平i型干扰素的新型复制缺陷型甲型流感病毒
HK40059786A (en) Expression system
EP2869841B1 (en) Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
Sureshkumar et al. Expression of Newcastle disease virus hemagglutinin-neuraminidase (HN) gene in mammalian expression vector.
Cai Live-attenuated vaccines against influenza viruses and role of NS1 in host response

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141224

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160506

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170113

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170224

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170502

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180411

R150 Certificate of patent or registration of utility model

Ref document number: 6324725

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees